These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37758349)

  • 21. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
    Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
    Fang C; Li XP; Gong WJ; Wu NY; Tang J; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():21-29. PubMed ID: 27873337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide Association Study on Platinum-induced Hepatotoxicity in Non-Small Cell Lung Cancer Patients.
    Cao S; Wang C; Ma H; Yin R; Zhu M; Shen W; Dai J; Shu Y; Xu L; Hu Z; Shen H
    Sci Rep; 2015 Jun; 5():11556. PubMed ID: 26100964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on Sotorasib (AMG 510) for
    Zhang SS; Nagasaka M
    Lung Cancer (Auckl); 2021; 12():115-122. PubMed ID: 34675734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immune checkpoint inhibitors-related severe hepatotoxicity in the treatment of non-small lung cancer: a case report].
    Liu DW; Fan JT; He XH; Hu JR; Wang YX; Li ZL
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1325-1326. PubMed ID: 34915645
    [No Abstract]   [Full Text] [Related]  

  • 28. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
    J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O; Kaira K; Kawasaki T; Mouri A; Hashimoto K; Shiono A; Shinomiya S; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Mochida S; Kagamu H
    Thorac Cancer; 2020 Apr; 11(4):1045-1051. PubMed ID: 32068351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
    Yun J; Nakagawa R; Tham K
    J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CodeBreak 200: Sotorasib Has Not Broken the KRAS
    Zhang SS; Lee A; Nagasaka M
    Lung Cancer (Auckl); 2023; 14():27-30. PubMed ID: 37101895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Ceddia S; Landi L; Cappuzzo F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA Approves First KRAS Inhibitor: Sotorasib.
    Cancer Discov; 2021 Aug; 11(8):OF4. PubMed ID: 34158284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.
    Cancer Discov; 2022 Apr; 12(4):878-879. PubMed ID: 35373275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
    Zenke Y; Umemura S; Sugiyama E; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Goto K
    Lung Cancer; 2016 Sep; 99():1-3. PubMed ID: 27565905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sotorasib effective in KRAS-mutant NSCLC.
    Sidaway P
    Nat Rev Clin Oncol; 2021 Aug; 18(8):470. PubMed ID: 34140669
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a
    Ming Z; Yongqiang Z; Zijin Z; Yan X; Di C; Xiaoxin T
    Pharmacogenomics; 2019 Nov; 20(16):1119-1124. PubMed ID: 31686598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
    Sharma P; Singh N; Sharma S
    J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.